Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 5/20 | 0.39 |
| ▸ | BCL2 | P10415 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | SCN1A | P35498 | 6/20 | 0.36 |
| ▸ | SCN5A | Q14524 | 6/20 | 0.36 |
| ▸ | SCN8A | Q9UQD0 | 6/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | SCN1B | Q07699 | 2/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.34 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.33 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.33 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL175753 | 1.00 | ALDH1A1 (0.42) | ALDH1A1KDM4EMCL1BCL2HPGD | |
| SCHEMBL175752 | 1.00 | ALDH1A1 (0.42) | ALDH1A1KDM4EMCL1BCL2HPGD | |
| Hydrochloric Acid SCHEMBL7300448 | 0.98 | ALDH1A1 (0.41) | ALDH1A1KDM4EMCL1BCL2HPGD | |
| SCHEMBL7288378 | 0.84 | PIK3CA (0.36) | ALDH1A1KDM4ESCN1ASCN5ASCN8A | |
| SCHEMBL6211278 | 0.83 | SCN9A (0.35) | ALDH1A1KDM4ESCN1ASCN5ASCN8A | |
| SCHEMBL6616473 | 0.83 | SCN9A (0.35) | ALDH1A1KDM4ESCN1ASCN5ASCN8A | |
| Hydrochloric Acid SCHEMBL6498236 | 0.81 | SCN9A (0.34) | ALDH1A1KDM4ESCN1ASCN5ASCN8A | |
| Gabapentin SCHEMBL3169310 | 0.78 | ALDH1A1 (0.48) | ALDH1A1KDM4EMCL1BCL2HPGD | |
| SCHEMBL7299956 | 0.76 | KDM4E (0.35) | ALDH1A1KDM4EHPGDSCN1ASCN5A | |
| SCHEMBL9217841 | 0.74 | FPR2 (0.32) | SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2021354-A2 | N-TERMINALLY MODIFIED GLP-1 RECEPTOR MODULATORS | Brystol-Myers Squibb Company (US) | 2009-02-11 | — | — | EP | claimed |
| US-20080045461-A1 | N-TERMINALLY MODIFIED GLP-1 RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-21 | — | — | US | claimed |
| EP-1883652-A2 | N-TERMINALLY MODIFIED GLP-1 RECEPTOR MODULATORS | Bristol-Myers Squibb Company (US) | 2008-02-06 | — | — | EP | claimed |
| WO-2007140284-A2 | N-TERMINALLY MODIFIED GLP-1 RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-06 | — | — | WO | claimed |
| US-20070021346-A1 | N-terminally modified GLP-1 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY | 2007-01-25 | — | — | US | claimed |
| WO-2006127948-A2 | N-TERMINALLY MODIFIED GLP-1 RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-11-30 | — | — | WO | claimed |
| US-12077611-B2 | Cyclic peptides multimers targeting α4β7 integrin | ZEALAND PHARMA A/S (DK) | 2024-09-03 | — | — | US | disclosed |
| US-20230406884-A1 | CYCLIC PEPTIDES MULTIMERS TARGETING ALPHA-4-BETA-7 INTEGRIN | ZEALAND PHARMA A/S (DK) | 2023-12-21 | — | — | US | disclosed |
| US-11713338-B2 | Cyclic peptides multimers targeting α-4-β-7 integrin | ZEALAND PHARMA A/S (DK) | 2023-08-01 | — | — | US | disclosed |
| US-11111273-B2 | Cyclic peptides multimers targeting alpha-4-beta-7 integrin | ZEALAND PHARMA A/S (DK) | 2021-09-07 | — | — | US | disclosed |
| US-20200216501-A1 | CYCLIC PEPTIDES MULTIMERS TARGETING ALPHA-4-BETA-7 INTEGRIN | ZEALAND PHARMA A/S (DK) | 2020-07-09 | — | — | US | disclosed |
| US-20100331245-A1 | PEPTIDE YY ANALOGS | IPSEN PHARMA S.A.S. (FR) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11111273-B2 | Cyclic peptides multimers targeting alpha-4-beta-7 integrin | ITGB7, ITGB4, ITGA4 | ALDH1A1 2543/4885KDM4E 2725/4885MCL1 860/4885 |
| US-20070021346-A1 | N-terminally modified GLP-1 receptor modulators | GLP1R, GIPR, IAPP | ALDH1A1 4813/4885KDM4E 2276/4885MCL1 1521/4885 |
| US-12077611-B2 | Cyclic peptides multimers targeting α4β7 integrin | ITGB7, ITGB4, ITGA4 | ALDH1A1 2492/4885KDM4E 2602/4885MCL1 863/4885 |
| US-20080045461-A1 | N-TERMINALLY MODIFIED GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, IAPP | ALDH1A1 4829/4885KDM4E 2366/4885MCL1 1531/4885 |
| US-20200216501-A1 | CYCLIC PEPTIDES MULTIMERS TARGETING ALPHA-4-BETA-7 INTEGRIN | ITGB7, ITGB4, ITGA4 | ALDH1A1 2543/4885KDM4E 2725/4885MCL1 860/4885 |
| US-20230406884-A1 | CYCLIC PEPTIDES MULTIMERS TARGETING ALPHA-4-BETA-7 INTEGRIN | ITGB7, ITGB4, ITGA4 | ALDH1A1 2543/4885KDM4E 2725/4885MCL1 860/4885 |
| US-20100331245-A1 | PEPTIDE YY ANALOGS | VIP, GLP1R, GIPR | ALDH1A1 4862/4885KDM4E 2051/4885MCL1 2696/4885 |
| US-11713338-B2 | Cyclic peptides multimers targeting α-4-β-7 integrin | ITGB7, ITGB4, ITGA4 | ALDH1A1 2752/4885KDM4E 2786/4885MCL1 793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.